Zhengxingu Capital
VC Fund
Zhengxingu Capital is an investment firm.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Zhengxingu Capital invests in
Stages Zhengxingu Capital invests in
Countries Zhengxingu Capital invests in
Investment Focus
Industry
- Biotechnology 4 (50%)
- Health Care 3 (38%)
- Biopharma 1 (13%)
- Biometrics 1 (13%)
- Organic Food 1 (13%)
Stage
- Series A 2 (25%)
- Series C 2 (25%)
- Series B 1 (13%)
- Series D 1 (13%)
- Venture - Series Unknown 1 (13%)
Country
- China 6 (75%)
- United States 1 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
|
Shanghai Eagtop Electronic Technology is a passive power electronics manufacturer and supplier.EAGTOP is a specialized in researching, developing and manufacturing passive power electronics devices. Our main products include film capacitor, laminated busbar, liquid cooling plates, composite superconducting flat heat pipe, 3D phase change heatsink, reactor, resistor, braking unit, EMC filter and so on. EAGTOP has passed the certification of quality management system ISO9001:2008 and ISO/TS16949-2009.EAGTOP is constantly committed to pioneering and innovating products in its industry, and provides highly competitive and comprehensive solutions to the electronic passive device for worldwide customers. Our products are used in various fields, such as industrial drive, new energy, railway transportation, power quality, etc. In persistent pursuit of fully understanding customers’ demands and putting effort into conducting collaborative R&D together with our customers, we strive to improve the user experience and create value for our customers to the largest extent. | Venture - Series Unknown / Jul 03, 2022 | |
|
|
Frontera Therapeutics is an AAV gene therapy company with the mission to establish a low-cost and scalable platform, to develop and produce high-quality and affordably priced rAAV therapies for the global market. | $160M / Series B / Jun 24, 2022 | |
|
|
Alit positioned as a supplier of instruments, equipment and technical services in the life science and biotechnology industries, the company has developed several series of products from Biotech, Altair, Rigel and Mira after launching its self-developed Countstar IC1000 cell analyzer in 2011. | $14.7M / Series A / May 13, 2022 | |
|
|
Alit positioned as a supplier of instruments, equipment and technical services in the life science and biotechnology industries, the company has developed several series of products from Biotech, Altair, Rigel and Mira after launching its self-developed Countstar IC1000 cell analyzer in 2011. | $14.7M / Series A / May 13, 2022 | |
|
|
ABclonal Technology is a rapidly growing life science research and diagnostic reagents provider. With scientists from world-class universities, the company thrives on improving the quality of life science research by providing high-quality antibodies, proteins, ELISA kits, NGS library preparation kits and molecular enzymes. | $189.1M / Series D / Dec 08, 2021 | |
|
|
Sciwind Biosciences is a developers of drugs intended to treat metabolic disorders. The company's drugs contain protein and peptide candidates for non-alcoholic steatohepatitis, enabling physicians to treat their patients in an enhanced way. | $69.8M / Series C / Oct 11, 2021 | |
|
Xiaoxian Dun
|
Xiaoxian Dun is a healthy food products company. | Series C / Mar 31, 2021 | |
|
|
Zhishan Weixin Biotechnology integrates gene-drug research and development to treat genetic and neurodegenerative diseases. The company focuses on the research and development and subversive production of rAAV gene drugs. Zhishan Weixin's therapeutic areas cover blood diseases, rare diseases, and other disease areas. | Series A / Feb 09, 2021 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Zhengxingu Capital invest in?
Zhengxingu Capital invests primarily in Biotechnology, Health Care and Biopharma startups, most often at Series A and Series C stage. Most of the 8 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Zhengxingu Capital last invest?
The most recent investment recorded for Zhengxingu Capital closed in Jul 2022. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!